🏢 官网IRVSTMDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 19:30:00(美东 07:30)·⟳ 抓取 19:33:26回填·⚡ 决策 10-22 19:34:51·5.1 天前
Verastem Oncology（VSTM）仅预告11月5日发布Q3 2026财报并召开电话会，无任何业绩数字
这是一份纯程序性财报日期/电话会预告，不含营收、利润、指引、订单或临床数据，不产生预期差；真正催化在2026-11-05实际财报，应在当日依据相对一致预期的surprise独立研判。
📄 原文VSTM↗ 原文
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
PDF Version BOSTON --(BUSINESS WIRE)--Oct. 22, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company com…
不做 Verastem Oncology（VSTM.US）
纯Q3财报电话会日期/网播日程预告，无营收、利润、指引、销售或临床增量，方向中性、无预期差与可交易edge；待2026-11-05实际财报发布后据surprise独立研判
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Verastem仅宣布Q3财报电话会日期（11月5日16:30 ET），无任何业绩或管线增量，属例行日程通知，方向中性、无edge，故不做；待财报实际发布再评估。
关键理由
- 无做多/做空依据：稿件不含任何财务、指引或临床增量，不构成催化
主要风险
- 财报将于11月5日发布，若提前基于日程稿建仓，实际业绩surprise方向未知且无法在本稿中预判
反向证据
- 做多前查反向 · 来源 web · 影响 none
本稿及已处理记录中无任何提前披露的Q3业绩、指引或销售数据，不存在支持提前做多的增量；亦无利空
检索:Verastem VSTM Q3 2026 preliminary results guidance FAKZYNJA sales preannouncement 原文 ↗
先例如何影响了这次决策
对本次决策的影响:确认本次按NO_INCREMENTAL_FACT不做，等待实际财报
方向:无可对照先例；本臂近72小时已处理多份同类Q3财报日期预告（SERV、TRIP、BXC、DKNG、ARQT、MDGL等），均判定为无增量、不做
涨幅量级:不适用——日程预告本身无价格反应可校准，真正幅度需待11月5日财报后用同类biopharma业绩先例衡量
形态:同类date-holder稿一致为中性、无交易edge
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 3,654 ms
{"result": "search_processed_events:agent query=`verastem oncology third quarter 2026 financial results conference call | vstm q3 2026 earnings webcast november 5 2026`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26094 条本臂决策(完整)，返回 10 条候选。\n• 10-22 11:04 UTC(北京 19:04) [bm25:56%] 不做 SERV.US (wire) — Serve Ro
原文全文
展开原文 · 1,576 字
PDF Version
BOSTON
--(BUSINESS WIRE)--Oct. 22, 2026--
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2026 financial results and business updates on
Thursday, November 5, 2026
, at
4:30 pm ET
.
A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website,
https://investor.verastem.com/events
. A replay of the webcast will be archived and available following the event.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI
®
FAKZYNJA
®
CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit
www.verastem.com
and follow us on
LinkedIn
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20261022618570/en/
For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com
or
media@verastem.com
Source: Verastem Oncology
BOSTON
--(BUSINESS WIRE)--Oct. 22, 2026--
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2026 financial results and business updates on
Thursday, November 5, 2026
, at
4:30 pm ET
.
A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website,
https://investor.verastem.com/events
. A replay of the webcast will be archived and available following the event.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI
®
FAKZYNJA
®
CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. For more information, please visit
www.verastem.com
and follow us on
.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20261022618570/en/
For Investor and Media Inquiries:
Julissa Viana
Senior Vice President, Corporate Communications,
Investor Relations & Patient Advocacy
investors@verastem.com
or
media@verastem.com
Source: Verastem Oncology
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
caf1c15f65· 2026-10-22 19:34 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前